ECSP045113A - Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta - Google Patents

Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Info

Publication number
ECSP045113A
ECSP045113A EC2004005113A ECSP045113A ECSP045113A EC SP045113 A ECSP045113 A EC SP045113A EC 2004005113 A EC2004005113 A EC 2004005113A EC SP045113 A ECSP045113 A EC SP045113A EC SP045113 A ECSP045113 A EC SP045113A
Authority
EC
Ecuador
Prior art keywords
selective agonists
benzopiranos
strogen
beta
receiver
Prior art date
Application number
EC2004005113A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045113A publication Critical patent/ECSP045113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a nuevos benzopiranos de cicloalquilo y derivados de los mismos, a composiciones que contienen estos compuestos, a su uso como agonistas selectivos del receptor estrogénico beta y a su uso en el tratamiento de enfermedades mediadas por el receptor estrogénico beta tales como cáncer de próstata, hiperplasia prostática benigna, cáncer testicular, cáncer de ovario, cáncer de pulmón, enfermedades cardiovasculares, trastornos neurodegenerativos, incontinencia urinaria, trastornos del sistema nervioso central (SNC), trastornos del tracto gastrointestinal (GI) y osteoporosis
EC2004005113A 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta ECSP045113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
ECSP045113A true ECSP045113A (es) 2004-07-23

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005113A ECSP045113A (es) 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Country Status (23)

Country Link
US (1) US7217734B2 (es)
EP (1) EP1448544B1 (es)
JP (1) JP4381810B2 (es)
KR (1) KR100950616B1 (es)
CN (1) CN1312147C (es)
AT (1) ATE362471T1 (es)
AU (1) AU2002359283B2 (es)
CA (1) CA2467013C (es)
CY (1) CY1106726T1 (es)
DE (1) DE60220179T2 (es)
DK (1) DK1448544T3 (es)
EA (1) EA007382B1 (es)
EC (1) ECSP045113A (es)
ES (1) ES2286322T3 (es)
HR (1) HRP20040439A2 (es)
HU (1) HU229351B1 (es)
IL (3) IL161325A0 (es)
MX (1) MXPA04004703A (es)
NO (1) NO328563B1 (es)
NZ (1) NZ531850A (es)
PL (1) PL205733B1 (es)
PT (1) PT1448544E (es)
WO (1) WO2003044006A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406373T1 (de) * 2003-04-21 2008-09-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CN101052641A (zh) 2004-09-07 2007-10-10 惠氏公司 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
CA2578300A1 (en) * 2004-10-18 2006-04-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CA2587669A1 (en) * 2004-11-18 2006-05-26 Janssen Pharmaceutica N.V. Novel 2h-chromene derivatives as selective estrogen receptor modulators
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US9974776B2 (en) 2013-12-05 2018-05-22 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma
CN108884124A (zh) 2015-09-17 2018-11-23 俄亥俄州创新基金会 碳硼烷化合物及其使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
KR100263137B1 (ko) 1995-09-08 2000-08-01 오테스코그 페르 오판 수용체
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2002542187A (ja) 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
IL150463A0 (en) 1999-12-30 2002-12-01 Signal Pharm Inc Compounds and methods for modulation of estrogen receptors
AU2001256164A1 (en) * 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
JP2003528858A (ja) 2000-03-27 2003-09-30 アクゾ・ノベル・エヌ・ベー エストロゲン関連治療用のノンステロイド系四環式化合物
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
MXPA04004703A (es) 2004-08-19
NO20042583L (no) 2004-06-18
DK1448544T3 (da) 2007-10-08
ATE362471T1 (de) 2007-06-15
IL185867A (en) 2009-09-22
IL185867A0 (en) 2008-01-06
AU2002359283B8 (en) 2003-06-10
ES2286322T3 (es) 2007-12-01
CY1106726T1 (el) 2012-05-23
WO2003044006A1 (en) 2003-05-30
JP2005513027A (ja) 2005-05-12
CA2467013C (en) 2010-08-10
CN1589268A (zh) 2005-03-02
PL374510A1 (en) 2005-10-31
EA200400695A1 (ru) 2004-12-30
EA007382B1 (ru) 2006-10-27
HUP0402628A2 (hu) 2005-04-28
CA2467013A1 (en) 2003-05-30
DE60220179T2 (de) 2008-02-07
IL161325A (en) 2008-07-08
KR100950616B1 (ko) 2010-04-01
JP4381810B2 (ja) 2009-12-09
HRP20040439A2 (en) 2005-04-30
IL161325A0 (en) 2004-09-27
CN1312147C (zh) 2007-04-25
PT1448544E (pt) 2007-08-10
KR20040063963A (ko) 2004-07-15
NZ531850A (en) 2007-01-26
AU2002359283B2 (en) 2007-06-21
PL205733B1 (pl) 2010-05-31
NO328563B1 (no) 2010-03-22
DE60220179D1 (de) 2007-06-28
AU2002359283A1 (en) 2003-06-10
EP1448544B1 (en) 2007-05-16
US7217734B2 (en) 2007-05-15
HU229351B1 (en) 2013-11-28
EP1448544A1 (en) 2004-08-25
HK1068349A1 (en) 2005-04-29
US20040249167A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
ECSP045113A (es) Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta
CR20220470A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
PA8515101A1 (es) Compuestos que contienen benzamido-piperidina y compuestos relacionados
GT200200266A (es) Uso de ureas de benzotiazoles
UY29317A1 (es) Derivados novedosos pirrolidilo de compuestos heteroaromáticos
DE602004025460D1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
PL2444085T3 (pl) Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
SV2008002365A (es) Compuestos de quinolina heteroaromaticos ref. pc32593a
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
GT200000019A (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
BRPI0519201A2 (pt) moduladores de delta-opiàide tricÍclico
Li et al. 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
DE60140700D1 (de) Thienoi2,3-B pyridin-derivate als Antagonisten des Gonadotropin-freisetzenden Hormons
BR0112147A (pt) Tienopirrolidinonas
TW200726461A (en) Use of non-steroidal progesterone receptor modulators
Kamble et al. Diels–Alder Reaction of 2‐Ethenyl‐1, 3, 3‐trimethylcyclohexene with 4H‐Chromen‐4‐ones: A Convergent Approach to ABCD Tetracyclic Core of Marine Diterpenoids Related to Puupehenone and Kampanols